The constant consumption of magistral oral solutions and suspensions by newborns and children of the assessed hospital indicates the need for such preparations as a pediatric therapeutic alternative in this hospital.
Objective:Study the use of magistral oral solutions and suspensions in infants and children
at a university hospital.Methods:This is a descriptive study based on the analysis of the assessed hospital's
magistral drug request forms regarding the patients in the neonatal ICU,
Obstetrics, Pediatrics and Pediatric Emergency from January 2012 to December 2013.
The frequency of drug requests and dispensation was evaluated and the consumption
of each active ingredient of the preparations was expressed as number of “infant
defined daily dose” (iDDD) and of iDDD/100 bed-days.Results:A total of 657 forms were analyzed - a monthly average of 27 pediatric
preparations. The neonatal ICU accounted for 69.6% of these requests. Twenty-one
drug items were used, of which the most common were folinic acid (88 requests),
sulfadiazine (85) and captopril (73). The consumption of the active principle in
these preparations varied in number of iDDD, from 7.5 (hydralazine) to 16,520.0
(folic acid), and in number of iDDD/100 bed-days in the neonatal ICU, from 0.1
(zinc sulfate) to 146.1 (folic acid).Conclusions:The constant consumption of magistral oral solutions and suspensions by newborns
and children of the assessed hospital indicates the need for such preparations as
a pediatric therapeutic alternative in this hospital.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.